BioMarin Pharmaceutical Inc.
corporate_fare Company Profile
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for BMRN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for BMRN spans 10-Q, 8-K, 8-K/A.
Recent high-impact activity:
- BioMarin 10-Q Details $122.8M Q3 Loss, $4.2B Debt Load After Amicus Deal
- BioMarin Q3 Revenue Tops $1B but FY26 EPS Guidance Cut to $2.80-$3.10
- BioMarin Posts $122.8M Q3 Loss as Alesta Charge Hits Results
- BioMarin Pays $70M Upfront for Second Fabry Disease Therapy
- BioMarin Quantifies Alesta Acquisition Charges: ~$320M Pre-Tax Hit, ~$1.55 EPS Drag for 2026
Financial Snapshot
Short Interest & Short Volume
5.77 days to coverFINRA reported short interest of 14,122,815 shares in BMRN as of the October 30, 2026 settlement, a 17.2% increase from the prior period — about 5.8 days to cover at its recent average daily volume. On November 20, 2026, 47.3% of BMRN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.